With the COVID-19 pandemic compounding the difficulty many patients with neovascular age-related macular degeneration have visiting their physician often enough for adequate monitoring of the progression of their disease, researchers sought to evaluate the performance of the small, portable Notal Home optical coherence tomography (OCT) device, which has a 10° field of view (3 mm x 3 mm) and creates 88 B-scans with 34 µm of spacing. After the eyes of patients with wet or dry AMD were scanned with a conventional OCT device, patients were provided a 2-minute instructional video and asked to scan their own eyes using the home OCT device. Successful scans were completed by 93% of patients; median visual acuity of the other 7% was 20/66, compared with 20/30 for those who completed the imaging. Rates of agreement between the conventional and home OCT devices were 93% for detection of subretinal fluid, 96% for detection of no subretinal fluid, 91% for detection of intraretinal fluid, and 98% for detection of no intraretinal fluid. Among those who completed a survey regarding the home OCT device, 95% agreed or strongly agreed it was “easy to perform” the scan. The study authors not that upon commercial availability of the home OCT device, an artificial intelligence program will analyze the images and send a report to the physician if retinal fluid is detected.